Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial
暂无分享,去创建一个
S. Cummings | E. Vittinghoff | Karen C Johnson | B. Ettinger | K. Ensrud | R. Wallace | D. Grady | K. Johnson | V. Yankov
[1] J. Gallagher,et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. , 1999, American journal of obstetrics and gynecology.
[2] S Kamen,et al. The task force. , 1976, Journal of hospital dental practice.
[3] S. Cummings,et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. , 1998, The New England journal of medicine.
[4] I. Yeh,et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. , 2001, Fertility and sterility.
[5] S. Cummings,et al. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. , 1998, The Journal of clinical endocrinology and metabolism.
[6] S. Evans,et al. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post‐menopausal ages , 1996, Clinical endocrinology.
[7] Olof Johnell,et al. Hormone replacement therapy and risk of hip fracture: population based case-control study , 1998, BMJ.
[8] M. Kulldorff,et al. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. , 2003, JAMA.
[9] Susan R. Johnson,et al. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1996, JAMA.
[10] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[11] H. Genant,et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. , 1997, Archives of internal medicine.
[12] H. Genant,et al. Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. , 1992, American journal of obstetrics and gynecology.
[13] D. Felsenberg,et al. Three-year follow-up of the use of transdermal 17β-estradiol matrix patches for the prevention of bone loss in early postmenopausal women ☆ ☆☆ , 2001 .
[14] P. Delmas,et al. Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] H. Genant,et al. Low-Dose Esterified Estrogen Therapy: Effects on Bone, Plasma Estradiol Concentrations, Endometrium, and Lipid Levels , 1997 .
[16] R. Lindsay,et al. The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss , 1984, Obstetrics and gynecology.
[17] H. Genant,et al. Quantitative Computed Tomography of Vertebral Spongiosa: A Sensitive Method for Detecting Early Bone Loss After Oophorectomy , 1982, Annals of internal medicine.
[18] Dominique Mottier,et al. Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[19] R. Boyd,et al. Efficacy and Local Tolerance of a Low‐Dose, 7‐Day Matrix Estradiol Transdermal System in the Treatment of Menopausal Vasomotor Symptoms , 1996, Obstetrics and gynecology.
[20] H. Genant,et al. Low‐dosage micronized 17‐estradiol prevents bone loss in postmenopausal women , 1992 .
[21] S. Cummings,et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. , 2002, JAMA.
[22] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[23] S. Cummings,et al. Endogenous Hormones and the Risk of Hip and Vertebral Fractures Among Older Women , 1999 .
[24] H. Genant,et al. Low-dosage micronized 17ß-estradiol prevents bone loss inpostmenopausal women , 1992 .
[25] R. Lindsay,et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. , 2002, JAMA.
[26] G. Bachmann,et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. , 2001, Fertility and sterility.
[27] E. Oger,et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk , 2003, The Lancet.
[28] R. Recker,et al. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. , 1999, Annals of internal medicine.
[29] D. Felsenberg,et al. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women. , 2001, American journal of obstetrics and gynecology.
[30] U. Ulmsten,et al. Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. , 1997, American journal of obstetrics and gynecology.
[31] Robert B Wallace,et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.
[32] J. Adachi,et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. , 2002, Archives of internal medicine.
[33] S. Weiss,et al. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. , 1999, Obstetrics and gynecology.
[34] A. Tosteson,et al. Predictors of Difficulty When Discontinuing Postmenopausal Hormone Therapy , 2003, Obstetrics and gynecology.
[35] H. Ellman,et al. Randomised, Controlled Comparison of Transdermal Estradiol with Oral Conjugated Estrogens for the Relief of Hot Flushes , 2000 .
[36] M. Kulldorff,et al. The Effect of Low Dose Micronized 17β-Estradiol on Bone Turnover, Sex Hormone Levels, and Side Effects in Older Women: A Randomized, Double Blind, Placebo-Controlled Study1 , 2000 .
[38] K. Kerlikowske,et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.
[39] W. Good,et al. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women , 2002, Menopause.
[40] N. Weiss,et al. Risk of Endometrial Cancer in Relation to Use of Low‐Dose, Unopposed Estrogens , 1998, Obstetrics and gynecology.
[41] T. Naessén,et al. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. , 2002, American journal of obstetrics and gynecology.
[42] O. Johnell,et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. , 1998, BMJ.
[43] S. Weiss,et al. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss , 1999 .
[44] J. Gallagher,et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients , 1999 .
[45] J. Risteli,et al. Effects of low‐ and conventional‐dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women , 1996, European journal of clinical investigation.
[46] Valerie Beral,et al. Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.